For that reason, we performed WES and identified highly relevant variants in cardiac and cancer genes, such as PRDM16 (p.P878L) in ACT patient 2, and SYNM (p.V1004I), TTN (p.V27642M), and an EGFR (p.E868Nfs*35) variant in ACT-3. This evidence concerns the gene PRDM16 and cancer.